dc.contributor.author |
Li, Jing |
|
dc.contributor.author |
Chen, Hangxiang |
|
dc.contributor.author |
Zhou, Qi |
|
dc.contributor.author |
Hu, Liangkun |
|
dc.contributor.author |
Ma, Li |
|
dc.contributor.author |
Han, Hongyan |
|
dc.contributor.author |
Li, Wei |
|
dc.contributor.author |
Du, Rong |
|
dc.contributor.author |
Tian, Li |
|
dc.date.accessioned |
2022-11-18T10:00:04Z |
|
dc.date.available |
2022-11-18T10:00:04Z |
|
dc.date.issued |
2017-09-19 |
|
dc.identifier.citation |
Li, J., Chen, H., Zhou, Q., Hu, L., Ma, L., Han, H., ... & Tian, L. (2017). Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients. Pakistan Journal of Pharmaceutical Sciences, 30(5), 1651-1656. |
en_US |
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/14083 |
|
dc.description.abstract |
This study examined the effects and mechanisms of telmisartan in hypertensive patients with paroxysmal
atrial fibrillation (PAF). Hypertensive patients with PAF (n=120) were randomized into test (telmisartan) and control (amlodipine besilate) groups. The pretreatment and post treatment left atrial dimension (LAD), high-sensitivity Creactive protein (hs-CRP) levels, heart rate, blood pressure (BP), and recurrence times of atrial fibrillation (AF) were recorded. The pretreatment and post treatment heart rates and BPs did not differ in either group (P>0.05). The post treatment systolic BP (SBP) and diastolic BP (DBP) did not differ between the groups (SBP: test, 132±5mmHg; control, 133±6 mmHg; DBP: test, 82±4 mmHg; control, 83±4mmHg). The LAD (test, 36.7±5.1 mm; control, 31.3±4.1mm) and hs-CRP (test, 5.6±2.6mg/L; control, 3.1±1.9mg/L) levels declined significantly (P>0.05) after treatment in the telmisartan group but not in the control group. After treatment, the LAD (test, 31.3±4.1mm; control, 36.2±4.6mm), hsCRP (test, 3.1±1.9 mg/L; control, .2±2.3mg/L) levels, and AF recurrence times were markedly lower in the test group (22) compared with the control group (44). Thus, telmisartan reduced the AF recurrence rates, LAD, and hs-CRP levels. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi |
en_US |
dc.subject |
Telmisartan |
en_US |
dc.subject |
hypertension |
en_US |
dc.subject |
paroxysmal atrial fibrillation |
en_US |
dc.title |
Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients |
en_US |
dc.type |
Article |
en_US |